Why Women Need to Pay Attention to Femtech, Now!
Femtech is how new tech can help us live longer, healthier and with less burnout, especially for Black women and girls.
Femtech, short for female technology, covers digital tools, diagnostics, wearables, telehealth and medical devices built specifically for women’s health. From periods and fertility to menopause, HIV/STIs, pelvic health and beyond. The term was coined in 2016 to give a fast‑growing but long‑neglected field a clear identity and to attract serious investment and research attention.
Why should the HealthTalk Group care?
Femtech is not just more apps, it is a practical way to close care gaps, counter burnout and improve outcomes for women who are too often dismissed or underserved by the system, especially Black and women of colour. The UK and US data are unambiguous.
From heavy, painful or irregular periods, to inequities in childbirth outcomes, to HIV and chlamydia trends, we have work to do and femtech can help.
1) Periods, Fibroids and Menstrual Health: Why Early, Accurate, Stigma‑free Support Matters
Menstrual health is a life‑course issue, tied to educational attainment, mental health and long‑term wellbeing, yet adolescent girls often lack accurate information and timely diagnosis for menstrual disorders. Leading UK/US experts highlight that poor data, stigma and service gaps undermine girls’ health and futures.
New evidence from a large US cohort shows younger generations are menstruating earlier, with Black girls disproportionately starting earlier and experiencing more irregular cycles, patterns linked to later health risks if unmanaged. Early menarche (a girl’s first menstrual period) plus irregularity can predict adverse outcomes, the trend is strongest in racial minorities and low‑income groups.
One major driver of severe periods and pelvic pain is uterine fibroids, which affect many women but hit Black women harder, earlier onset, larger tumours, more severe symptoms and longer waits for treatment and diagnosis. UK reviews and position statements now warn that ethnic minority women are hardest hit, calling out systemic delays and the need for culturally competent care pathways.
US and global evidence echo this. Black women are ~3x more likely to have fibroids, with a heavier clinical and economic burden, NIH and clinical journals are investing in new diagnostics, risk models and therapies to close these gaps.
Where femtech helps:
Symptom and cycle tracking with clinical‑grade scales can flag heavy menstrual bleeding earlier and guide NICE‑aligned decisions in primary care.
Biomarker‑enabled tools (e.g., at‑home hormone testing) plus AI decision support can make perimenopause/menstrual diagnoses faster and less subjective, important for women who report being dismissed.
Tele‑gynecology and remote monitoring reduce travel and time off work, vital for women juggling caregiving and employment.
2) Pregnancy and Childbirth: Confronting the Inequities
In the UK, the 2024/25 findings are stark. Black women are almost three times more likely to die during or after pregnancy than White women and Asian women about twice as likely, disparities that have persisted with rising maternal mortality overall.
Parliamentary and government analyses link these inequities to leadership failures, bias, poor data and workforce pressures. Ethnic minority women also report low trust and not being listened to.
In the US, maternal mortality remains among the highest in the developed world and Black women face >3x the risk of pregnancy‑related death compared with White women. Even when overall deaths dip, the gap for Black mothers persists.
Where femtech helps:
AI‑supported maternity triage and risk tools can standardise red‑flag detection and reduce bias in time‑pressed consultations, so warning signs are not missed.
Lived‑experience‑informed AI training (e.g., VR modules) can help clinicians and employers understand cultural contexts and the realities of Black and Asian women’s experiences, improving trust and response times.
Integrated remote monitoring for blood pressure, glucose and mental health can catch problems earlier, reduce unnecessary visits and keep mothers safer postpartum. (Evidence base: mainstream maternal telehealth and AI trend analyses).
3) HIV and Chlamydia in Women: Progress and Persistent Inequalities
In the UK, the latest UKHSA report (through end‑2024) confirms progress toward 95‑95‑95 treatment goals and more testing overall, but persistent inequalities remain.
Black African heterosexual women and men experience higher positivity and more late diagnoses, with lower PrEP uptake than other groups. The Lancet highlights rising diagnoses among heterosexuals and the success of opt‑out ED testing, but warns gaps remain.
On STIs, UKHSA’s 2024 surveillance shows chlamydia remains the most common STI, with the highest rates in 15–24‑year‑olds and marked inequalities by ethnicity and region.
While chlamydia diagnoses decreased in 2024, young women remain a priority group and UKHSA tables document ethnic disparities in STI rates.
In the US, women still account for nearly 1 in 5 new HIV diagnoses and Black women bear a disproportionate burden relative to their share of the population. National briefs show declines overall but stubborn inequities in incidence, diagnosis and outcomes for women of colour.
Where femtech helps:
AI‑driven outreach and risk tools can increase HIV testing and PrEP uptake among women who don’t see themselves as “at risk.” UK statistics show lower PrEP access in Black African heterosexual women, underlining the need for targeted digital engagement.
At‑home postal testing + digital follow‑up lowers stigma and time barriers, UKHSA and NAT call for broader online access and data‑driven targeting to reach women earlier.
Youth‑centred sexual health apps can address early risk, consent and care navigation, with parliamentary evidence reminding us that services are stretched and young people, some Black ethnic groups and GBMSM remain disproportionately affected by STIs.
4) Burnout & Midlife: Femtech for Longevity and Everyday Load
Women carry the bulk of unpaid care and face time‑poor, appointment‑poor realities that drain energy and worsen health outcomes.
Femtech’s promise is practical. Asynchronous care, structured symptom data, AI‑guided self‑management and workplace training that recognise menopause, menstrual disorders and mental load as health and productivity issues, not private burdens.
UK and US market trackers confirm femtech is scaling quickly, fuelled by AI, wearables and telehealth, meaning more clinically validated options are coming to mainstream employers and NHS/US systems.
5) What should HealthTalk Group Members Do Next?
Get baseline‑smart on your body
Use NICE‑aligned heavy menstrual bleeding guidance to understand when “heavy” is clinically significant and track symptoms consistently. Bring structured data to appointments.
Choose privacy‑first, evidence‑based tools
Look for platforms with clear data policies and clinical validation. For menstrual issues, fibroids, fertility or perimenopause, favour tools that generate clinician‑ready reports and align to UK/US guidelines.
If you are Black or a woman of colour, insist on equitable care
Know the stats. Higher fibroid burden, earlier menarche trends, higher risks in maternity and inequities in HIV/STI outcomes. Ask your provider about objective tests (e.g., biomarkers, imaging), request clear escalation plans and use digital records to document symptoms over time.
For leaders/employers in HealthTalk Group
Adopt VR/AI cultural‑competency training for managers and clinical partners (e.g., MenopauseXR), ensure benefits cover remote gynae consults and partner with services that can ship at‑home tests and provide PrEP education tailored to women.
For advocates and programme leads
Demand disaggregated data (by ethnicity, age, socioeconomic status) from vendors. Commission audits for algorithmic bias and publish outcomes by subgroup, not averages. These steps make tech a lever for equity, not just efficiency.
The Strategic Takeaway Is Simple
Women, especially Black women and girls, cannot afford to ignore femtech. The data show earlier periods and heavier symptoms for many, worse pregnancy outcomes in both the UK and US and persistent inequalities in HIV/STIs.
But they also show solutions. AI‑enabled diagnostics, privacy‑first tracking, VR training, postal testing and integrated care that can prevent crises, cut burnout and extend healthy years.
This is not about swapping clinicians for apps, it is about giving women and providers better tools to act earlier, faster and more fairly.
If this resonates, like, comment and share so more women, especially Black women and girls, see it and get the support they deserve.
If you have tried a femtech tool that actually helped, share your experience below. Let us learn from each other and push organisations and providers to adopt equitable, evidence‑based tech.
Disclaimer
This article is for information and education only. It does not replace individualised medical advice. If you are experiencing symptoms or have concerns, please speak with your GP, an NHS sexual health clinic or a qualified clinician in your region.
